Form 8-K · Current Report · Filed 2024-06-03
Amgen Inc. Approves Equity Incentive Plan and Elects Directors
On May 31, 2024, Amgen Inc. held its Annual Meeting of Stockholders where the Amgen Inc. Second Amended and Restated Equity Incentive Plan was approved by stockholders. Additionally, all 12 nominees for director were elected to serve a one-year term.
- Filer
- Amgen Inc. AMGN · NASDAQ
- Filed
- Accession
- 0001193125-24-153221
- CIK
- 0000318154
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Submission of Matters to a Vote of Security Holders
Market reaction
Close before filing
$305.85
Next session
+0.5%
Since filing
+25.9%
Latest close
$385.16
What happened, not what will happen — closing prices around the filing date.
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Never miss another AMGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.